Pertussis: persistent pathogen, imperfect vaccines

Referance

• Brennan M, Strebel P, George H et at Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis. J. Infect. Dis. 181, 210–215 (2000).
   Google Scholar
• Gehanno JF, Pestel-Caron M, Nouvellon M, Caillard JE Nosocomial pertussis in healthcare worders from a pediatric emergency unit in France. Infect. Control Hosp. 431demiol. 20, 549–552 (1999).
   Google Scholar
• Centers for Disease Control and Prevention. Pertussis outbreak — Vermont 1996. MVIWR 46, 8226 (1997).
   Google Scholar
• de Melker HE, Conyn-van Spaendonck MAE, Rumke HC, Wijngaarden JK van, Mooi FR, Schellekens JFP. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole cell vaccine. Emerg. Infect. Dis. 3, 175–178 (1997).
   Google Scholar
• Van der Zee A, Groenendijk H, Peeters M etal The differenciation of B. parapertussis and B. bronchiceptka from man and animals as determinded by DNA polymorphism mediated by two different insertion sequence elements suggests their phylogenetic relationship. Lit. j Syst. Bacteriol 46, 640–647 (1996).
   Google Scholar
• Huang CC, Chen PM, Kuo JK et al. Experimental whooping cough. N Engl. J. Med 266, 105–111 (1962).
   PubMed Web of Science ®Google Scholar
• Ashworth LAE, Fitzgeorge RB, Irons LI, Morgan CP, Robinson A. Rabbit nasopharyngeal colonization by Bordetella pertussis: the effects of immunization on clearance and on serum and nasal antibody levels. Hyg. Camb. 88, 475–486 (1982).
   Google Scholar
• Hornibrook JVV, Ashburn LL. A study of experimental pertussis in the young rat. Pub. Health Rep. 54, 439–444 (1939).
   Google Scholar
• Halperin SA, Heifetz SA, Kasina A. Experimental respiratory infection with Barktaapertussis in mice: Comparison of two methods. Clin. Invest. Med. 11, 297–303 (1988).
   Google Scholar
• Parton R Review of the biology of Bonietella pertussis. Biolofflcals27, 71–76 (1999).
   Google Scholar
• Goldman WE, Klapper DG, Baseman JB. Dectection, isolation and analysis of a released Barktella pertussis product toxic to cultured tracheal cells. Infect. Immun. 36, 782–794 (1982).
   Google Scholar
• Heininger U. Recent progress in clinical and basic pertussis research. Ear j Pecliatr 160, 203–213 (2001).
   PubMed Web of Science ®Google Scholar
• •Contains survey of European vaccination schedules.
   Google Scholar
• Weiss AA, Hewlett EL, Myers GA, Falkow S. Pertussis toxin and extracytoplasmic adnylate cydase as virulence factors of Barktella pertussis. Infect. Immun. 43, 263–269 (1984).
   PubMedGoogle Scholar
• Mattoo S, Miller JF, Cotter PA. Role of Barktella bronchiseptka fimbriae in tracheal colonization and development of a humoral immune response. Infect. Immun. 68, 2024–2033 (2000).
   Google Scholar
• Cotter PA, Miller JE Genetic anaylsis of Bordetella—host interaction. Ann. NY Acad. Li. 797, 65–76 (1996).
   PubMedGoogle Scholar
• Brennan MJ, Li ZM, Cowell JL eta]. Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Barktella pertussis. Infect. Immun. 56, 3189–3195 (1988).
   Google Scholar
• Hewlett EL. A commentary on the pathogenesis of pertussis. Clin. Infect. Dis. 23\(Suppl. 2), S94-98 (1999).
   Google Scholar
• Pittman M. The concept of pertussis as a toxin-mediated disease. Pediatr Infect. Dis. J 3, 467–486 (1984).
   Web of Science ®Google Scholar
• Wirsing von Konig CH, Pmger H. Role of pertussis toxin in causing symptoms of Bomfetella parapertuds infection. Eur I Clin. Mavbiol Infect Dis. 13, 455–458 (1994).
   PubMedGoogle Scholar
• Toyota T, Kai Y, Kakizaki Metal. Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies). Tohoku Exp. Med 130, 105–16 (1980).
   Google Scholar
• Mattoo S, Foreman-VVykert AK, Cotter PA, Miller JE Mechanism of Bordetella pathogeneisis. Front. Biosa. 6, E168–186 (2001).
   Google Scholar
• Cherry JD. The epidemiology of pertussis and pertussis immunization on in the United Kingdom and the United States: a comparative study. CUIT: Pro& Pedlar]: 14, 1–78 (1984).
   Google Scholar
• Centers for Disease Control and Prevention: Pertussis — United States, January 1992—June 1995. MIIWR 44, 525–529 (1995).
   PubMedGoogle Scholar
• Centers for Diseases Control and Prevention. Pertussis — United States, 1997–2002, M44WR51 (04), 76 (2002).
   Google Scholar
• Bass JVV, Stephenson SR. The return of pertussis. Pediatr Infect. Dis. 6, 141–144 (1978).
   Google Scholar
• Mertsola J, Ruuskanen 0, Eerola E, Viljanen MK. Intrafamilial spread of pertussis. Pediatr 103, 359–363 (1983).
   Google Scholar
• Cromer BA, Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA. Unrecognized pertussis infections in adolescents. Am Ds. Child 147, 575–577 (1993).
   PubMedGoogle Scholar
• Cattaneo LA, Reed GVV, Haase DH, Wills MJ, Edwards KM. The seroepidemiology of Bordetella pertussis infection: A study of persons ages 1–65. J Infect Dir173, 1256–1259 (1996).
   Google Scholar
• Yih WK, Lett SM, de Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults 1989–1998.1 Ds. 182, 1409–1416 (2000).
   Google Scholar
• Wright SW Decker MD, Edwards KM. Incidence of pertussis infection in healthcare workers. Infect. Control Hosp. 431demio120, 120–123 (1999).
   Google Scholar
• Mink CM, Cherry JD, Christ PD eta]. A search for Bordetella pertussis infection in university students. Clin. Infect. Dis. 14, 464–471 (1992).
   PubMed Web of Science ®Google Scholar
• Schmitt-Grohe S, Cherry JD, Heininger U, Uberall MA, Pineda E, Stehr A. Pertussis in German adults. Clin. Infect. Dis. 21, 860–866 (1995).
   PubMed Web of Science ®Google Scholar
• Wright SW Edwards KK, Decker Decker M, Seldin ME. Pertussis infection in adults with persistent cough. JA/VIA 273, 1044–1046 (1995).
   Google Scholar
• Ward JI, APERT Study Group: Pertussis epidemiology and acellular pertussis vaccine efficacy in older children: NIH APERT multi-center pertussis trial. Pediatric Academic Socie0 (Meeting, Abst #752816 (2001).
   Google Scholar
• Mortimer EA Jr. Pertussis and its prevention: a family affair. J Infect. Dis. 161, 473–479 (1990). Review of epidemiology of pertussis transmission.
   Google Scholar
• Valenti WM, Pincus PH, Messner MK. Nosocomial pertussis: possible spread by a hospital visitor. Am. J Dir. Child. 134, 520–527 (1980).
   Google Scholar
• Beller A, Lewis K, Pinecla EF, Cherry JD. Unrecognized maternal peripartum pertussis with subsequent fatal neonatal pertussis. Obstet. Gynecology 82, 691–693 (1993).
   PubMedGoogle Scholar
• Lee LH, Pichichero ME. Costs of illness due to Borrktella pertussis in families. Arrh. Fain. Med. 9, 989–996 (2000).
   PubMedGoogle Scholar
• Cherry JD, Heininger U. Pertussis and other Bordetella infections. In: Textbook of Pediatric Infectious Diseases (4th Ed.). Feigin RD, Cherry JD (Eds.), VVB Saunders Comp., Philadelphia, PA, USA (1998).
   Google Scholar
• Mannerstedt G. Pertussis in adults. J Pediatr 5, 596–600 (1934).
   Google Scholar
• Maclean DIN. Adults with pertussis. Royal College Gen. Practitioners 32, 298–300 (1982).
   PubMedGoogle Scholar
• Aoyama T, Takeuchi Y, Goto A, Iwai H, Murase Y, Iwata T Pertussis in adults. Am. Di. Child 146, 163–166 (1992).
   PubMedGoogle Scholar
• Senzilet LD, Halperin SA, Spilka JS et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin. Infect. Dis. 32, 1691–1687 (2001).
   PubMed Web of Science ®Google Scholar
• Long SS, Welkon Ci, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. j Infect. Dir. 161, 480–486 (1990).
   Google Scholar
• Deen JL, Mink CM, Cherry JD et al. A household contact study of Bordetella pertussis infections. Clin. Infect. Dis. 21, 1211–1219 (1995).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Wang EEL, Law B eta]. Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: Report of the Immunization Monitoring Program-Active (IMPACT). Clin. Infect. Dir. 28, 1238–1243 (1999).
   Google Scholar
• De Serres G, Shadmani R, Duval B eta]. Morbidity of pertussis in adolescents and adults.J Infect. Dis. 182, 174–179 (2000).
   Google Scholar
• Deek S, De Serres G, Boulianne N et al. Failure of physicians to consider the diagnosis of pertussis in children. Clin. Infect. as 28, 840–846 (1999).
   PubMedGoogle Scholar
• Muller FM, Hoppe JE, Wirsing von Konig CH. Laboratory diagnosis of pertussis: State of the art in 1997. J Clin. Mcrobiol 35, 2435–2443 (1997). Detailed review of laboratory diagnosis.
   Google Scholar
• Murphy T, Bisgard K, Sanden G. Diagnosisand laboratory methods. In: Guidelines for the Control of Pertussis Outbreaks. Centers for Disease Control and Prevention, Atlanta, GA, USA (2000).
   Google Scholar
• Jackson LA, Cherry JD, VVang SP, Grayston JT. Frequency of serologic evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses. Clin. Infect. Dis. 31, 3–6 (2000).
   PubMed Web of Science ®Google Scholar
• Lievano FA, Reynolds MA, Waring AL et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin. Mcrobiol 40, 2801–2805 (2002).
   PubMed Web of Science ®Google Scholar
• Hoppe JE. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis. Infection 26, 242–246 (1998).
   PubMed Web of Science ®Google Scholar
• Bass JVV, Klenk EL, Kotheimer JB et al. Antimicrobial treatment of pertussis. Pediatr 75, 768–781 (1996).
   Google Scholar
• Booher CE, Farrell JB, West EJ. Pertussis: Clinical comparison of the newer antibiotics. J. Pecliatr 38, 411–422 (1951).
   Google Scholar
• Report of the Medical Research Counsel. Treatment of whooping-cough with antibiotics. Lancetl, 1109–1112 (1953).
   Google Scholar
• Weinstein L, Seltser R, Marrow CT The treatment of pertussis with aureomycin, chloramphenicol and terramycin. f Pedlar!: 39,549–59 (1951).
   Google Scholar
• Lewis K, Saubolle MA, Tenover FC, Rudinsky ME, Barbour SD, Cherry JD. Pertussis caused by an erythromycin-resistant strain of Borrktella pertussis. Pediatric Infect. Bis.f 14,388–391 (1995).
   PubMedGoogle Scholar
• Korgenski EK, Daly JA. Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West Region of the United States. J Clin. Myrobiol 35,2989–2991 (1997).
   PubMed Web of Science ®Google Scholar
• Wison KE, Cassiday PK, Popovic T, Sanden GN. Barktella pertussis isolates with a heterogeneous phenotype for erythromycin resistance. J Clin. Mcrobiol 40,2942–2944 (2002).
   PubMedGoogle Scholar
• Bergquist S, Bemander S, Dansjo H, Sundelof B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr. Infect. B/s.f 6, 458–461 (1987).
   PubMed Web of Science ®Google Scholar
• Hoppe JE, Erythromycin Study Group. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. Pediatr. Infect. B/s.f 11,189–193 (1992).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of erythromycin estolate is as effective as fourteen days for treatment of Barktella pertussis infections. Pediatrics100,65–71 (1997).
   Google Scholar
• Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr. Infect. Dis. 20,1149–1154 (2001).
   Google Scholar
• Amoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. f Pediatr. 129,761–764 (1996).
   Google Scholar
• Bace A, Zmic T, Begovac J, Kuzmanovic N, Culig J. Short-term treatment of pertussis with azithromycin in infants and young children. Eur. f Clin. Mcrobiol Infect. Dis. 18,296–298 (1999).
   Google Scholar
• Biellik RJ, Patriarca PA, Mullen JR etal. Risk factors for community- and household-acquired pertussis during a large-scale outbreak in Central Wisconsin. J Infect. Dis. 157,1134–1141 (1998).
   Google Scholar
• Sprauer MA, Cochl SL, Zell ER etal. Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am. J Dis. Child 146,177–181 (1992).
   Google Scholar
• De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr. Infect. Dis. 14,969–975 (1995).
   Google Scholar
• Wirsing von Konig CH, Postels-Multani S, Bogaerts H et al. Factors influencing the spread of pertussis in households. Eur Pediatr. 157,391-394 (1998).
   Google Scholar
• Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Borrktella pertussisinfection. Pediatrics104, e42 (1999).
   Google Scholar
• Honein MA, Paulozzi LJ, Himelright IM etal. Infantile hypertophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 354,2101–2105 (1999).
   PubMed Web of Science ®Google Scholar
• Bruss JB, Siber GR. Protective effects of pertussis immunoglobulin (P-MG) in the aerosol challenge model. Clin. Diag. Lab. Immun. 6,464–470 (1999).
   PubMedGoogle Scholar
• Bruss JB, Malley R, Halperin S etal. Treatment of severe pertussis: a study of the safety and pharmacology of iv. pertussis immunoglobulim Pediatr. Infect. B/s.f 18, 505–511 (1999).
   Google Scholar
• Krantz I, Norrby SR, Trollfors B. Salbutamol versus placebo for treatment of pertussis. Pecliati: Lied. Dis. 4,638-640 (1985).
   Google Scholar
• Roberts I, Gavin R, Lennon D. Randomized controlled trial of steroids in pertussis. Pediatr. Infect 1)isj 11,982–983 (1992).
   Google Scholar
• Edwards KM, Decker MD, Mortimer EA. Pertussis Vaccine. In: Vaccines (3rd Ed.). Plotkin SA, Orenstein WA (Eds). VVB Saunders Comp., Philadelphia, PA, USA (1999). Comprehensive evaluation and critique of all pertussis vaccines.
   Google Scholar
• Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis Vaccine 15, 1907-1916 (1998).
   Google Scholar
• Cherry JD, Gombein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Borrktella pertussis cough illnesses. Vaccine 16,1901–1906 (1998).
   PubMed Web of Science ®Google Scholar
• Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH. Barktella pertussis respiratory infection in children is associated with preferential activation of Type 1 T-helper cells. J Infect. Dis. 175, 1246–1250 (1997).
   Google Scholar
• He Q, Tran Mink NH, Edelman K, Viljanen MK, Arvilommi H, Mertsola J. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin and pertactin of Borrktella pertussis in the peripheral blood mononudear cells of infected and immunized schoolchildren and adults. Infect 'MIMI?. 66, 3796–3801 (1998).
   PubMedGoogle Scholar
• Ausiello CM, Urbani F, Sala A, Lande R, Cassone A. Vaccine- and antigen-dependent Type 1 and Type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. infect. immun. 65,2168-2174(1997).
   Google Scholar
• Zepp F, Knuf M, Habermehl P et al. Pertussis-specific cell-medicated immunity in infants after vaccination with tricomponent acellular pertussis vaccine. Infect. Immun. 64,4078–4084 (1996).
   PubMed Web of Science ®Google Scholar
• Salmaso S, Mastrantonio P, Wassilak SGF et al. Persistence of protection through 33 months of age provided by immunization in infantcy with two three-component acellular pertussis vaccines. Vaccine 13,1270–1275 (1998).
   Google Scholar
• Mahon BP, Brady MT, Mills KH. Protection against Borrktella pertussis in mice in the absence of detectable circulating antibody: Implications for long-term immunity in children. J Infect. Dis. 181,2087-2091 (2000).
   Google Scholar
• Olin P, Storsaeter J. Vaccine efficacy. In: A Clinical Blot of Acellular Pertussis Vaccines in Sweden: Technical Report. Stockholm, National Bacteriolgocial Laboratory, 1–28 (1988).
   Google Scholar
• Madsen T vaccination against wooping cough. /A/VIA 101,187–188 (1933).
   Google Scholar
• Schmitt H-J, Wirsing von Konig CH, Neiss A etal. Efficacy of a two-component acellular pertussis vaccine in early childhood after household exposure. JAMA 275,37–41 (1996).
   Google Scholar
• Liese JG, Meschievitz CK, Harzer E eta]. Effiacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect. B/s.f 16,1038–1044 (1997).
   PubMed Web of Science ®Google Scholar
• Simondon F, Prezisosi MP, Yam A et al. A randomized double-blind trial comparing a 307,1171–1176 (1993).
   Google Scholar
• Stehr K, Cherry JD, Heininger U et at A comparative efficacy trial in Germany in infants who received either the Lederle/ Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP vaccine or DT vaccine). Pediatrics101, 1–11 (1998).
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hallander HO, Olin P etal A controlled trial of a two component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Eng1.1 Med 334,349–355 (1996).
   Google Scholar
• Greco D, Salmaso S, Mastrantonio P etal. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl. Mea! 334,341–348 (1996).
   Google Scholar
• Onorato IM, Wassilak SG, Mead B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JA/V/4 267,2745–2749 (1992).
   Google Scholar
• Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and Pertussis immunization and serious acute neurologic illnesses in children. Br. Med. J. following pertussis and rubella vaccines:.
   Google Scholar
• Blumberg DA, Lewis K, Mink CM, Christenson PD, Chatfield P, Cherry JD. Severe reactions associated with diphtheria—tetanus—pertussis vaccine: detailed study of children with seizures, hyptonic—hyporesponsive episodes, high fevers and persistent crying. Pediatrics 91,1158–1165 (1993).
   PubMed Web of Science ®Google Scholar
• DuVemoy TS, Braun MM. Hypotonic—hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998. Pediatrics 106, e52 (2000).
   PubMedGoogle Scholar
• Miller DL, Wadsworth MJH, Ross EM. Pertussis vaccine and severe acute neurologic illnesses. Response to a recent review by members of the NCES team. Vaccine7, 487–489 (1989).
   Google Scholar
• Summary of a report of the Institute of Medicine JA/V/A 2667,392-396 (1992) two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15, 1606–1612 (1997).
   PubMedGoogle Scholar
• Donnelly S, Loscher CE, Lynch MA, Mills KH. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: Evidence of a role for toxin-induced interleukinl beta in a new murine model for anaylsis of neuronal side effects of vaccination. Infect. Immun. 69,4217–4223 (2001).
   PubMedGoogle Scholar
• Trollfors B, Taranger J, Lagergard T etal A placebo-controlled trial of pertussis-toxoid vaccine. N Engl. Med. 333,1045–1050 (1995).
   PubMed Web of Science ®Google Scholar
• Liese JG, Stojanov S, Foeschle J etal Long-term efficacy of Biken acellular pertussis vaccine. Presented at NIAID Acellular Pertusssi Vaccine Conference, Bethesda, MD, USA, November 12–14, (2000).
   Google Scholar
• Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole-cell pertussis compoent vaccine. FIR: Pediatr 161,142–146 (2002).
   Google Scholar
• Cherry JD. Comparative efficacy of acellular pertussis vaccines: An analysis of recent trials. Pediatr Infect. Dis.116 (Suppl. 4), S90-96 (1997).
   Google Scholar
• Decker MD, Edwards KM, Steinhoff MC et al. Comparison of 13 acellular pertussis vaccines: Adverse reactions. Pediatrics 96, 557–566 (1995).
   PubMed Web of Science ®Google Scholar
• Rennels MB, Deloria MA, Pichichero ME et al. Extensive swelling after booster doses of acellular pertusis—tetanus—diphtheria vaccines. Pediatrics105, e12 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs. whole-cell pertussis vaccine. A postmarketing assessment. Arrh. Pediatr Adolesc. Med 150,457–460 (1996).
   Google Scholar
• Centers for Disease Control and Prevention. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MI/IWR49, 1–8 (2000).
   Google Scholar
• Greenberg DP, Pickering LK, Senders SD et al. Interchangeability of 2 diphtheria—tetanus—acellular pertussis vaccines in infancy. Pediatrics 109,666–72 (2002).
   PubMed Web of Science ®Google Scholar
• Bartels I, Jungert J, Lugauer S, Stehr K, Heininger U. Immunogenicity and reactogenicity of a single dose of a diphtheria—tetanus—acellular pertussis component vaccine (DTaP) compared to diphtheria—tetanus toxoid (Td) and a diphtheria toxoid (d) in adults. Vaccine 19, 3137–3145 (2001).
   Google Scholar
• Schmitt HJ, Mohnike K, Zepp F, Herden P, Hosbach P Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults. Vaccine 19,403–408 (2000).
   PubMedGoogle Scholar
• Halperin SA, Smith B, Russell M etal Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect. B/s.f 19,276–283 (2000).
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular booster vaccination in England and Wales. Vaccine 20,1316–1330 (2002).
   PubMed Web of Science ®Google Scholar
• Yeh SH, Ward JI, Cherry J, Miller JF, Cotter P, Reiman D. Bordetella pertussis human challenge studies: Evaluation of pathogenesis and immunologic determinants of susceptibility, infection and protection. Presented at the NIAID Acellular Pertussis Vaccine Conference, Bethesda, MD, USA, November 12–14 (2000).
   Google Scholar
• Weingart CL, Mobberley-Schuman PS, Hewlett EL, Gray MC, Weiss AA. Neutralizing antibodies to adenyl cydase toxin promote phagocytosis of Borrktella pertussisby human neutrophils. Infect. Immun. 68,7152–7155 (2000).
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nagai M, Funaishi K, Endoh M. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine. Vaccine 19,1199–1203 (2000).
   PubMedGoogle Scholar
• Roduit C, Bozzotti P, Mielcarek N etal Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussisin a murine model: evidence for early control of pertussis. Infect. Immun. 70, 3521–3528 (2002).
   PubMed Web of Science ®Google Scholar